Despite a haemophilia market bustling with rivals, Qfitlia’s broad label and favourable dosing regimen could give it an upper ...

Basel: Novartis has announced the appointment of Karen Hale to the expanded role of Chief Legal and Compliance Officer for ...

In this episode of C&EN Uncovered, host Craig Bettenhausen speaks with C&EN assistant editor Laurel Oldach about the use of horseshoe crab blood in pharmaceutical endotoxin testing, the challenges of ...

Despite regulation changes in the Chinese healthcare industry, we think CSPC is well-positioned to maintain relatively strong revenue growth. First, generic drugs normally face the most severe price ...

Science Exchange, a leading provider of life sciences procurement and supplier management SaaS solutions, today announced the acquisition of HappiLabs, a Chicago-based software and services company ...

D-Wave Quantum Inc. ("D-Wave" or the "Company"), a leader in quantum computing systems, software, and services, and the pharmaceutical division of Japan Tobacco Inc. ("JT") today announced the ...

Typically, when organisations speak of supply chain transparency, they focus on the last mile: the product journey from “production to fork”, with a view to reducing energy and waste while optimising ...

In FY25, 58 equity mutual funds delivered double-digit returns, while 242 out of 268 posted gains. However, 26 funds recorded ...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced that it has received an official Filing Receipt from the United States Patent and ...

In addition, the Company has begun development of a formulation for rekvry™ – an alcohol misuse treatment for emergency and hospital settings. The Company believes that rekvry™ fulfills an unmet need ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

For prolonged antithrombotic treatment after percutaneous coronary intervention (PCI), clopidogrel monotherapy was more ...